We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Molecular Biology Test Detects Human Papillomavirus

By Biotechdaily staff writers
Posted on 30 Apr 2007
A molecular diagnostic test enables the detection of human papillomavirus (HPV) in cervical cancer surveillance.

Cervical cancer is caused in 99.7% of cases by persistent infection with HPV. More...
Most HPV infections are transient and do not induce cervical cancer. However, a small but significant number of HPV infections progress to cervical cancer. It is the expression of viral oncoproteins E6 and E7, which initiate the cervical cancer process, that makes them early cancer markers. It has also been demonstrated that genotypes 16 and 18 cause approximately 70% of cervical cancers worldwide.

Most cervical cancer surveillance methods currently in use detect viral DNA. Such testing, however, does not make it possible to most effectively assess the virus' oncogenicity. Developed by bioMérieux (Marcy l'Etoile, France), NucliSens EasyQ HPV is based on a new concept that benefits from all the latest discoveries in the field, directly determining the expression of oncogenic risk factors by detecting the mRNA of the E6 and E7 proteins.

NucliSENS HPV EasyQ is the first real-time amplification/detection test with this degree of automation to be CE-marked. It is currently available in France, the Netherlands, Belgium, Switzerland, Spain, and Austria and will be progressively marketed in other countries according to local regulations.

The test enhances the quality of women's lives by reducing the need for invasive examinations and treatments. "This new molecular diagnostic test reinforces bioMérieux's offer in the field of oncology. The test contributes to the fight against cancer and complements current methods for the detection and monitoring of cervical cancer. This new product strongly reinforces the value of our molecular biology platform, NucliSENS EasyQ, for our customers and future prospects,” said Stéphane Bancel, CEO of bioMérieux.

bioMérieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination to improve patient health and ensure consumer safety. The products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring.


Related Links:
bioMérieux

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The POC diagnostic test aims to use fingerstick blood, serum, or plasma sample to detect typhoid fever (Photo courtesy of Adobe Stock)

POC Test Uses Fingerstick Blood, Serum, Or Plasma Sample to Detect Typhoid Fever

Typhoid fever is an acute febrile illness caused by Salmonella enterica serovar Typhi (S. Typhi) and affects an estimated 11–21 million people globally each year, resulting in approximately 128,000–161,000... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Industry experts gather at WHX Labs Dubai to discuss how leadership must adapt as AI and automation transform the laboratory (Photo courtesy of Shutterstock)

WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories

WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.